On Tuesday, Alto Neuroscience, Inc. (NASDAQ:ANRO) announced an asset purchase agreement with Chase Therapeutics Corporation for a portfolio of dopamine agonist drug combinations for ...

The anti-inflammatory drug tocilizumab targets the IL-6 pathway to achieve a 54% remission rate in hard-to-treat depression.

Machine-learning iMAP coaching track achieves a 55% depression remission rate by personalizing lifestyle targets.

Flow Neuroscience, a small Swedish company treating depression with brain-stimulating headsets, released early data on Monday showing that its device relieved depressive symptoms in clinical trials.

– Issued and pending claims expected to protect ALTO-207 into the mid-2040s – MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical ...

This groundbreaking paper on the neuroscience of depression is one of the most fascinating mental health studies of 2025! It uncovers a potential central biological mechanism linking chronic stress to ...

Young women with depression are more likely to have lower levels of taurine in their hippocampus than healthy controls. The corresponding study was published in Biological Psychiatry. Between 2013 and ...

An experimental diagnostic tool in the form of a computer game was able to quickly identify patients with depression based on ...

Four in ten adults with chronic pain experience clinically significant depression and anxiety, reported a new systematic review and meta-analysis published in JAMA Network Open. "Right now, we have ...

Pretty much everyone can agree that the state of America’s collective mental health is lousy. But the jury is very much still out on what exactly is causing the problem. Of course, that’s a ...

The game can reliably detect depression in as little as three minutes, researchers reported May 18 in the Proceedings of the ...

You cannot think your way out of anxiety, but you can look your way out. Discover the neuroscience of awe and why feeling ...